Cyto-Facto T Cells for Transplantation and Production Method
Summary
Cyto-Facto Inc., with inventors Shin Kawamata and Takako Yamamoto, filed patent application US20260109948A1 for engineered human T cells lacking human leukocyte antigen (HLA) class I molecules and containing an exogenous ST6GALNAC6 gene. The application claims cells characterized by CD62L and CD45RA positivity, with ATP production of at least 400 pmol/min/10^5 cells and mitochondrial spare respiratory capacity of at least 40 pmol/min/10^5 cells, 5-6 days after proliferation stimulation. The invention aims to provide low-immunogenic human T cells capable of long-term engraftment for allogeneic CAR-T or TCR-T cell therapy applications.
“According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 227 changes logged to date.
What changed
The patent application discloses engineered human T cells combining HLA class I deficiency with exogenous ST6GALNAC6 expression. The cells exhibit specific phenotypic markers (CD62L+/CD45RA+) and enhanced metabolic parameters (total ATP production rate of 400 pmol/min/10^5 cells or more; mitochondrial spare respiratory capacity of 40 pmol/min/10^5 cells or more). These characteristics aim to enable stable, long-term engraftment after transplantation and support development of universal allogeneic CAR-T or TCR-T cell therapies.
This is an informational patent filing that creates no compliance obligations for competitors. No regulatory action is required from any party. Biotechnology and cell therapy developers may monitor this filing as an indicator of competitive activity in the allogeneic T cell engineering space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
T CELLS FOR TRANSPLANTATION AND PRODUCTION METHOD THEREOF
Application US20260109948A1 Kind: A1 Apr 23, 2026
Assignee
Cyto-Facto Inc.
Inventors
Shin KAWAMATA, Takako YAMAMOTO
Abstract
The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and/or (b):
(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol/min/105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol/min/105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.
CPC Classifications
C12N 5/0636 A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/32 A61K 40/50 C12N 5/0087 C12N 5/10 C12N 2510/00
Filing Date
2023-09-13
Application No.
19111668
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.